Published in Urology on August 01, 1999
Herbal therapy use by cancer patients: a literature review on case reports. Eur J Cancer (2010) 1.07
Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem J (2003) 1.06
The translational aspect of complementary and alternative medicine for cancer with particular emphasis on Kampo. Front Pharmacol (2015) 0.75
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst (1997) 3.92
Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res (2000) 3.71
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology (1997) 3.61
VCaP, a cell-based model system of human prostate cancer. In Vivo (2001) 3.36
Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst (1998) 2.83
Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology (2001) 2.34
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med (1991) 2.07
The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem (1986) 2.07
Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol (2000) 1.97
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
Bladder tumor detection at virtual cystoscopy. Radiology (2001) 1.74
Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol (2000) 1.70
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology (1998) 1.69
E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol (2001) 1.68
The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia (2008) 1.60
Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res (2000) 1.54
Retracted Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin Cancer Res (2000) 1.46
A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome. J Cell Sci Suppl (1984) 1.43
Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev (2001) 1.41
Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res (1991) 1.35
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol (2000) 1.33
Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. J Urol (1989) 1.26
Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res (1999) 1.24
Whole mounted radical prostatectomy specimens do not increase detection of adverse pathological features. J Urol (2000) 1.22
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol (1998) 1.22
Experience with extra-adrenal pheochromocytoma. J Urol (1989) 1.20
Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol (2000) 1.18
Acquired rectourethral fistula: methods of repair. J Urol (1995) 1.17
The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol (2001) 1.16
Nuclear structure and the three-dimensional organization of DNA. J Cell Biochem (1991) 1.16
Nephron sparing surgery for suspected malignancy: open surgery compared to laparoscopy with selective use of hand assistance. J Urol (2000) 1.14
Experience with cardiopulmonary bypass and deep hypothermic circulatory arrest in the management of retroperitoneal tumors with large vena caval thrombi. Ann Surg (1990) 1.13
Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis (2000) 1.12
The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol (1977) 1.11
Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. Urology (1995) 1.10
Retracted Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. Urology (2001) 1.10
Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology (1994) 1.07
Decreased galectin-3 expression in prostate cancer. Prostate (2000) 1.07
Early castration reduces prostatic carcinogenesis in transgenic mice. Urology (1999) 1.07
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol (1999) 1.07
Assessment of early continence recovery after radical prostatectomy: patient reported symptoms and impairment. J Urol (2001) 1.06
The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer (2006) 1.04
Risk of multiple primary cancers in prostate cancer patients in the Detroit metropolitan area: a retrospective cohort study. Prostate (1997) 1.03
Paclitaxel in the treatment of hormone-refractory prostate cancer. Semin Oncol (1999) 1.01
The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol (1989) 1.00
Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol (1998) 1.00
Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res (1998) 0.99
Comparison of patients' and physicians' rating of urinary incontinence following radical prostatectomy. Semin Urol Oncol (2000) 0.99
Clinical and in vitro magnetic resonance imaging of prostatic carcinoma. AJR Am J Roentgenol (1984) 0.98
Staging of prostate cancer. Cancer (1994) 0.97
Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst (2000) 0.96
Bilateral emphysematous pyelonephritis. Urology (1985) 0.96
Tumor-associated angiogenesis in prostate cancer. Anticancer Res (1994) 0.96
The tissue matrix: cell dynamics and hormone action. Endocr Rev (1990) 0.96
Preferential adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to extracellular matrix components in vitro. Clin Cancer Res (2000) 0.95
Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively? J Urol (2001) 0.95
The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res (1996) 0.94
Retroperitoneal neural sheath tumors: Cleveland Clinic experience. J Urol (1989) 0.94
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology (2005) 0.94
Phenotypic characterization of immortalized normal and primary tumor-derived human prostate epithelial cell cultures. Prostate (2000) 0.93
Cancer as a complex adaptive system. Med Hypotheses (1996) 0.93
Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. Prostate (1993) 0.92
Hormone resistance in prostate cancer. Cancer Metastasis Rev (1999) 0.91
Selective screening device for the early detection of normal or delayed cognitive development in infants at risk for later mental retardation. Pediatrics (1986) 0.90
Collagen injection for the treatment of incontinence after cystectomy and orthotopic neobladder reconstruction in women. J Urol (2000) 0.90
Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. Urology (2000) 0.90
Combination radiation and chemotherapy for the treatment of squamous cell carcinoma of the male and female urethra. J Urol (1995) 0.90
Radical cystectomy without radiation therapy for carcinoma of the bladder. J Urol (1984) 0.90
Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate (2000) 0.90
Genetic characterization of immortalized human prostate epithelial cell cultures. Evidence for structural rearrangements of chromosome 8 and i(8q) chromosome formation in primary tumor-derived cells. Cancer Genet Cytogenet (2000) 0.89
Galectin-3 is a nuclear matrix protein which binds RNA. Biochem Biophys Res Commun (1995) 0.89
Nuclear matrix proteins in normal and breast cancer cells. Cancer Res (1993) 0.88
Stomal complications of intestinal conduit urinary diversion. Cleve Clin J Med (1989) 0.87
Intra-arterial chemotherapy as an adjuvant to surgery in transitional cell carcinoma of the bladder. J Urol (1986) 0.87
Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol (2000) 0.87
Anesthetic management for surgical removal of renal carcinoma with caval or atrial tumor thrombus using deep hypothermic circulatory arrest. J Cardiothorac Anesth (1989) 0.87
Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer (1994) 0.87
Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol (1989) 0.87
Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate (1999) 0.87
Preneoplastic alterations in nuclear morphology that accompany loss of tumor suppressor phenotype. J Natl Cancer Inst (1991) 0.87
Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. Int J Cancer (1995) 0.86
Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol (1990) 0.86
Recent trends in incidence and treatment of prostate cancer among elderly men. J Natl Cancer Inst (1995) 0.86
Clinical management of premalignant lesions of the prostate. WHO Collaborative Project and Consensus Conference on Public Health and Clinical Significance of Premalignant Alterations in the Genitourinary Tract. Scand J Urol Nephrol Suppl (2000) 0.86
The psychosocial aspects of sexual recovery after prostate cancer treatment. Int J Impot Res (2009) 0.86
Lymphadenectomy in renal adenocarcinoma. J Urol (1982) 0.86
An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer. Anticancer Res (1995) 0.85
Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. Urology (2000) 0.85
Prospective comparison between hand-assisted laparoscopic and open surgical nephroureterectomy for urothelial cell carcinoma. Urology (2001) 0.85
Vitamins A and E: further clues for prostate cancer prevention. J Natl Cancer Inst (1998) 0.84
Revascularization of the kidney after occlusion of the aorta and both renal arteries. Surgery (1976) 0.84
A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. Cancer Lett (1993) 0.84
Cutaneous ureterostomy as palliative diversion in adults with malignancy. Urology (1987) 0.83
Radical cystectomy for carcinoma of the bladder in the elderly patient. J Urol (1987) 0.83
Free flap phalloplasty. J Urol (1982) 0.83